[A novel Cisplatin delivery system for malignant ascites-bearing mice-a basic experimentation]

Gan To Kagaku Ryoho. 2011 Nov;38(12):2081-3.
[Article in Japanese]

Abstract

The authors used 70% deacetylated chitin and cisplatin (CDDP) to devise a novel anticancer drug delivery system (DDS). We examined in vitro release of the CDDP from the system. The novel system was intraperitoneally( ip) given to malignant ascites-bearing mice, and the survival time of each animal was recorded. The related oncolytic mechanism was immunologically investigated. More than 70-90% of the CDDP was gradually delivered from the system in 24 hours. Nineteen animals among 30 treated with our system survived for longer than 4 weeks, and a recurrence of ascites was nil. A 4- week survival rate of the animals with ip injected conventional CDDP was 5/14. All non-treated animals had massive ascites and died within 4 weeks. Immunologic studies suggested that cytotoxic immunoresponse was induced in the mice treated with the novel system. Our newly devised system warrants for clinical applications in the treatment of malignant ascites.

Publication types

  • English Abstract

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use
  • Ascites / drug therapy*
  • Ascites / etiology
  • CD8-Positive T-Lymphocytes / immunology
  • Cell Line, Tumor
  • Cisplatin / administration & dosage*
  • Cisplatin / therapeutic use
  • Drug Delivery Systems
  • Injections, Intraperitoneal
  • Mice
  • Neoplasm Transplantation
  • Peritoneal Neoplasms / complications
  • Peritoneal Neoplasms / drug therapy*
  • Peritoneal Neoplasms / immunology

Substances

  • Antineoplastic Agents
  • Cisplatin